Indication

Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.

Medicine details

Medicine name:
vedolizumab (Entyvio)
SMC ID:
SMC2276
Pharmaceutical company
Takeda UK Ltd
BNF chapter
Gastro-intestinal system
Submission type
Abbreviated
Publication due date:
10 August 2020